Jan 11, 2023 / 07:15PM GMT
Richard Vosser - JPMorgan Chase & Co, Research Division - Senior Analyst
Welcome to the Merck KGaA from Darmstadt Germany presentation at the 41st JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst at JPMorgan. And it's my great pleasure to introduce the CEO of Merck KGaA, Belen Garijo, but before I hand over to Belen, I would just remind you that we're staying here for questions first time. And we will do them using a mic, so please put your hand up and we'll get to your questions after Belen's presentation. Belen, welcome to the conference.
Belen Garijo Lopez - MERCK Kommanditgesellschaft auf Aktien - Chair of Executive Board & CEO
Thank you so much, Richard, for the introduction. And good morning, everyone. Happy new year to all of you. I'm super excited to be here in person, finally, after several years of virtuality, as we call it, so what I would like to do during the next 20 minutes is to take you through a brief strategy update as well as give you a bit additional information and additional color on our two major business
Merck KGaA at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot